RecruitingPhase 2NCT06264388

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ashish Shah
Principal Investigator
Ashish Shah, MD
University of Miami
Intervention
DB107-RRV(drug)
Enrollment
33 enrolled
Eligibility
18-75 years · All sexes
Timeline
20242034

Study locations (1)

Collaborators

Denovo Biopharma LLC · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06264388 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials